Pulmonary Cryptococcal Infection Complicating Gefitinib Therapy in a Patient With EGFR L858R-Positive Lung...

Area of Science:

• Oncology
• Infectious Diseases
• Pulmonology

Background:

• Epidermal Growth Factor Receptor (EGFR)-mutant lung adenocarcinoma is a distinct subtype of non-small cell lung cancer.
• EGFR-tyrosine kinase inhibitors (TKIs) like gefitinib are standard treatments for EGFR-mutant lung adenocarcinoma.
• Development of new pulmonary nodules can occur during EGFR-TKI therapy.

Purpose of the Study:

• To highlight the importance of considering secondary pulmonary cryptococcosis in patients with EGFR-mutant lung adenocarcinoma receiving EGFR-TKIs.
• To differentiate new pulmonary nodules caused by infection from tumor progression.

Main Methods:

• Retrospective analysis of clinical data.
• Review of imaging findings.
• Pathological correlation.

Main Results:

• New pulmonary nodules in patients on EGFR-TKIs can represent opportunistic infections, not solely disease progression.
• Secondary pulmonary cryptococcosis presents as new nodules in this patient population.
• Timely diagnosis of cryptococcosis is essential for appropriate treatment.

Conclusions:

• Clinicians should consider secondary pulmonary cryptococcosis in the differential diagnosis of new pulmonary nodules in patients with EGFR-mutant lung adenocarcinoma treated with EGFR-TKIs.
• Avoiding premature attribution of new nodules to disease progression can lead to earlier diagnosis and treatment of fungal infections.